Assure Reports a Record Number of Monthly Procedures in October 2020
Company Launches Two IONM-Related Clinical Research Projects DENVER, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or...
Month: November 2020
Tonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020 Phase 1 Safety Study in Humans...
Exagen Inc. To Participate in November Investor Conferences
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients...
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
Strengthens Monopar’s Validive IP Portfolio To 2035 WILMETTE, Ill., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR),...
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
AGEN1181: New clinical responses and intratumoral Treg depletion AGEN1777 (TIGIT) is Fc enhanced for optimized immune performance & broader benefit...
Cassava Sciences Reports Third Quarter 2020 Financial Results
AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s...
New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells
Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11,...
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory...
BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting
Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®) NEW HAVEN, Conn.,...
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
-- ORR of 64% Observed in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer -- ORR of 75% and One...
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered...
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Graphic Anti-SARS-COV-2 antibody response (IgG and IgM) to trimeric spike protein and RBD of SARS-CoV-2. Patients received a 0.3, 1.0...
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases
State-of-the-art facility to be located in Bedford, Massachusetts NOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a...
Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020
Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based...
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression...
Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
44.0% objective response rate and 10.3-month median progression-free survival observed in non-small cell lung cancer (NSCLC) cohort Phase 3 registration-enabling...
Celldex Presents Data from Oncology Portfolio at SITC 2020
-- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated----Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09,...
Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter
Highlights: Revenue of $145.2 million up 56% sequentially in quarter ended Sept. 30, 2020 GAAP operating income increased $28.7 million...